Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 5 years of Preferred Stock Liabilities data on file, last reported at $114.7 million in Q1 2026.

• Preferred Stock Liabilities for Q1 2026 came in at $114.7 million, down 20.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $114.7 million (down 20.42% YoY), and the FY2025 annual result was $131.0 million, down 8.31% from the prior year.
• Preferred Stock Liabilities retreated to $114.7 million in Q1 2026 per RYTM's latest filing, from $131.0 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $146.9 million in Q3 2025 and troughed at $114.7 million in Q1 2026.
• A 3-year average of $138.3 million and a median of $142.2 million in 2024 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2025 and 2026: Preferred Stock Liabilities rose 3.81% in 2025, then declined 20.42% in 2026.
• A 3-year view of Preferred Stock Liabilities shows it stood at $142.8 million in 2024, then retreated by 8.31% to $131.0 million in 2025, then dropped by 12.41% to $114.7 million in 2026.
• Business Quant data shows RYTM's Preferred Stock Liabilities at $114.7 million in Q1 2026, $131.0 million in Q4 2025, and $146.9 million in Q3 2025.